Humacyte Inc
HUMA
Company Profile
Business description
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Contact
2525 East North Carolina Highway 54
DurhamNC27713
USAT: +1 919 313-9633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
220
Stocks News & Analysis
stocks
Going into earnings, is Tesla stock a buy, a sell, or fairly valued?
Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,293.20 | 45.10 | -0.48% |
CAC 40 | 8,212.73 | 24.14 | 0.29% |
DAX 40 | 23,979.92 | 292.27 | -1.20% |
Dow JONES (US) | 46,084.27 | 132.03 | 0.29% |
FTSE 100 | 9,377.18 | 58.91 | -0.62% |
HKSE | 25,247.10 | 641.41 | -2.48% |
NASDAQ | 22,612.54 | 50.01 | 0.22% |
Nikkei 225 | 47,582.15 | 695.59 | -1.44% |
NZX 50 Index | 13,289.21 | 99.89 | -0.75% |
S&P 500 | 6,643.90 | 14.83 | 0.22% |
S&P/ASX 200 | 8,995.30 | 34.70 | -0.38% |
SSE Composite Index | 3,839.76 | 76.47 | -1.95% |